An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism.

MLA

Yeatts, Sharon D., et al. “An Adaptive Clinical Trial Design to Identify the Target Dose of Tenecteplase for Treatment of Acute Pulmonary Embolism.” Clinical Trials (London, England), vol. 19, no. 6, Dec. 2022, pp. 636–46. EBSCOhost, https://doi.org/10.1177/17407745221105897.

APA

Yeatts, S. D., Foster, L. D., Barsan, W. G., Berry, N. S., Callaway, C. W., Lewis, R. J., Saville, B. R., Silbergleit, R., & Kline, J. A. (2022). An adaptive clinical trial design to identify the target dose of tenecteplase for treatment of acute pulmonary embolism. Clinical Trials (London, England), 19(6), 636–646. https://doi.org/10.1177/17407745221105897

Chicago

Yeatts, Sharon D, Lydia D Foster, William G Barsan, Nicholas S Berry, Clifton W Callaway, Roger J Lewis, Benjamin R Saville, Robert Silbergleit, and Jeffrey A Kline. 2022. “An Adaptive Clinical Trial Design to Identify the Target Dose of Tenecteplase for Treatment of Acute Pulmonary Embolism.” Clinical Trials (London, England) 19 (6): 636–46. doi:10.1177/17407745221105897.